Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALA-SCALP vs NOXIVENT
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.
Noxivent is a synthetic analog of epinephrine that acts as a non-selective alpha and beta adrenergic receptor agonist. It binds to alpha-1 receptors causing vasoconstriction, alpha-2 receptors reducing insulin secretion, beta-1 receptors increasing heart rate and contractility, and beta-2 receptors causing bronchodilation and vasodilation. Its primary effect in septic shock is increasing mean arterial pressure via vasoconstriction.
Treatment of minimally to moderately thick actinic keratoses of the scalp (Grade 1 or 2) in immunocompetent patients,Off-label: other photosensitivity disorders
Increase blood pressure in adults with septic shock who remain hypotensive despite adequate fluid resuscitation and treatment with vasopressors (e.g., norepinephrine) and inotropes (e.g., dobutamine) to maintain mean arterial pressure ≥65 mm Hg
Topical application of a 5% solution to the scalp twice daily.
700 mg orally twice daily with food.
Not applicable; topical ALA-SCALP is not significantly absorbed systemically. After systemic absorption from photodynamic therapy, terminal half-life is approximately 1 hour due to rapid metabolism.
Terminal elimination half-life 4-6 hours; prolonged in renal impairment (up to 12 hours) requiring dose adjustment.
ALA is metabolized intracellularly via the heme biosynthesis pathway to protoporphyrin IX (Pp IX).
Primarily metabolized by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT) in the liver and other tissues. Also undergoes oxidation and conjugation.
Primarily renal elimination of metabolites; <1% excreted unchanged in urine. Biliary/fecal excretion is negligible.
Primarily renal (70-80% unchanged), with 10-15% biliary/fecal. Minor metabolism via ester hydrolysis.
Not characterized; systemic levels are negligible after topical administration.
85-90% bound to albumin; reduced binding in hypoalbuminemia.
Not applicable for topical route. If systemic exposure occurs, Vd is approximately 0.5 L/kg, consistent with distribution into total body water.
0.8-1.2 L/kg; suggests extensive tissue distribution (e.g., lung, liver).
Topical: Systemic bioavailability is minimal (<1%) due to poor percutaneous absorption and rapid local metabolism.
Oral: 50-60% (first-pass metabolism); Sublingual: 70-80%; No data for other routes.
No dose adjustment required for renal impairment.
GFR 30-59 m L/min: 350 mg twice daily; GFR <30 m L/min or on dialysis: 350 mg once daily.
No dose adjustment required for hepatic impairment.
Child-Pugh A: no adjustment; Child-Pugh B: 350 mg twice daily; Child-Pugh C: not recommended.
Safety and efficacy in pediatric patients have not been established.
Not approved for pediatric use.
No specific dose adjustment recommended; use with caution due to potential increased sensitivity.
No specific dose adjustment; monitor renal function and use lowest effective dose.
No FDA black box warning.
None.
Photosensitivity: avoid exposure to sunlight or bright indoor light (e.g., examination lamps, operating room lamps) for at least 40 hours post-application.,Application site reactions: severe stinging, burning, erythema, and edema may occur.,Use sun-protective measures (e.g., wide-brimmed hat, sunscreen) after treatment.,Do not apply to eyes or mucous membranes.
May cause severe hypertension, cardiac arrhythmias (especially with pre-existing conditions), tissue ischemia due to vasoconstriction, and exacerbation of heart failure. Use with caution in patients with hyperthyroidism, diabetes (as it increases blood glucose), and history of coronary artery disease.
Hypersensitivity to aminolevulinic acid or any component of the formulation,Cutaneous photosensitivity at wavelengths of 400-450 nm,Porphyria
Hypersensitivity to noxivent or any component; uncontrolled hypertension; tachyarrhythmias; ventricular fibrillation; use with non-selective MAO inhibitors (risk of hypertensive crisis).
No known food interactions. No dietary restrictions required.
No specific food interactions reported. Grapefruit juice may increase formoterol levels (avoid if possible). Take with or without food.
No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.
NOXIVENT is a combination of a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS). Inhaled beta-agonists have low systemic bioavailability and are generally considered low risk in pregnancy. Studies with inhaled corticosteroids (budesonide, fluticasone) show no increased risk of major malformations. First-trimester exposure data for LABAs are limited but do not indicate a significant teratogenic risk. However, high-dose systemic corticosteroids are associated with cleft palate. Inhaled doses minimize systemic exposure. Overall, NOXIVENT is considered safe for use in pregnancy when asthma control is necessary.
Minimal systemic absorption; unlikely to appear in breast milk. M/P ratio not established. Considered compatible with breastfeeding.
No data on NOXIVENT specific M/P ratio. Both components (beta-agonist and corticosteroid) are excreted in human milk in small amounts, but are unlikely to affect the infant due to low oral bioavailability. Inhaled doses result in minimal systemic concentrations. The American Academy of Pediatrics considers inhaled beta-agonists and corticosteroids compatible with breastfeeding. Use with caution, especially with high doses.
No dosage adjustment required; pharmacokinetics unlikely altered due to topical route.
No dose adjustment required for NOXIVENT based on pharmacokinetic changes in pregnancy. Asthma management guidelines recommend using standard doses to maintain control. However, pregnancy may alter asthma severity; dose titration is based on symptom control rather than pharmacokinetic adjustment. Consider step-down if asthma improves, step-up if worsens. Monitor for systemic effects of high doses (e.g., growth restriction from ICS).
ALA-SCALP is a topical aminolevulinic acid preparation used for photodynamic therapy of actinic keratoses on the scalp. Must be applied by a healthcare professional. Avoid sun exposure to treated area for 48 hours post-application due to photosensitivity. Do not apply to eyes or mucous membranes. Lesions should be prepped by gentle removal of scales and crusts. Use with a compatible light source (blue light). Burning and stinging during light exposure is common; consider pain management strategies.
NOXIVENT (formoterol + glycopyrrolate) is a fixed-dose LABA/LAMA combination for COPD. Avoid use in asthma due to increased risk of asthma-related death. Monitor for paradoxical bronchospasm; discontinue immediately if occurs. Assess renal function before initiating glycopyrrolate (primarily renally excreted). Not for acute bronchospasm relief.
This medication is applied by your doctor to treat precancerous spots on your scalp.,After application, you will need a special light treatment (photodynamic therapy).,Avoid sunlight and bright indoor light on the treated area for 48 hours after the procedure.,You may experience temporary redness, swelling, scaling, or discomfort at the treatment site.,Use sunscreen and protective clothing when going outdoors during the photosensitivity period.,Do not wash the treated area for at least 4 hours after the solution is applied.,Contact your doctor if you experience severe pain, blistering, or signs of infection.
Use exactly as prescribed; do not exceed recommended dose or frequency.,This medication is for maintenance treatment of COPD, not for acute symptoms. Always have a rescue inhaler (e.g., albuterol) available.,Rinse mouth with water after each dose to prevent thrush (oral candidiasis).,Report worsening breathing, chest tightness, or signs of allergic reaction (rash, hives, swelling) immediately.,Do not stop using NOXIVENT without consulting your doctor, even if you feel better.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALA-SCALP vs NOXIVENT, answered by our medical review team.
ALA-SCALP is a Topical Corticosteroid that works by ALA-SCALP (aminolevulinic acid) is a photosensitizer precursor that is converted intracellularly to protoporphyrin IX (Pp IX), which accumulates in cells with increased heme synthesis, such as rapidly dividing cells. Upon exposure to blue light (BLU-U®), Pp IX produces reactive oxygen species, leading to cellular damage and apoptosis of targeted cells.. NOXIVENT is a Beta-2 Agonist Bronchodilator that works by Noxivent is a synthetic analog of epinephrine that acts as a non-selective alpha and beta adrenergic receptor agonist. It binds to alpha-1 receptors causing vasoconstriction, alpha-2 receptors reducing insulin secretion, beta-1 receptors increasing heart rate and contractility, and beta-2 receptors causing bronchodilation and vasodilation. Its primary effect in septic shock is increasing mean arterial pressure via vasoconstriction.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALA-SCALP and NOXIVENT depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALA-SCALP is: Topical application of a 5% solution to the scalp twice daily.. The standard adult dose of NOXIVENT is: 700 mg orally twice daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALA-SCALP and NOXIVENT in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALA-SCALP is classified as Category C. No evidence of teratogenicity; topical application with minimal systemic absorption. First trimester: unlikely risk. Second/third trimester: no known fetal risks from maternal use.. NOXIVENT is classified as Category C. NOXIVENT is a combination of a long-acting beta-agonist (LABA) and an inhaled corticosteroid (ICS). Inhaled beta-agonists have low systemic bioavailability and are generally consid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.